CA2140140A1 - Lysozyme dimer and compositions containing the same - Google Patents

Lysozyme dimer and compositions containing the same

Info

Publication number
CA2140140A1
CA2140140A1 CA002140140A CA2140140A CA2140140A1 CA 2140140 A1 CA2140140 A1 CA 2140140A1 CA 002140140 A CA002140140 A CA 002140140A CA 2140140 A CA2140140 A CA 2140140A CA 2140140 A1 CA2140140 A1 CA 2140140A1
Authority
CA
Canada
Prior art keywords
lysozyme
manufac
ture
dimer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002140140A
Other languages
English (en)
French (fr)
Inventor
Witold Kiczka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nika Health Products Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2140140A1 publication Critical patent/CA2140140A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002140140A 1992-07-13 1993-07-13 Lysozyme dimer and compositions containing the same Abandoned CA2140140A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL92295273A PL173978B1 (pl) 1992-07-13 1992-07-13 Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
PLP-295273 1992-07-13

Publications (1)

Publication Number Publication Date
CA2140140A1 true CA2140140A1 (en) 1994-01-20

Family

ID=20058087

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002140140A Abandoned CA2140140A1 (en) 1992-07-13 1993-07-13 Lysozyme dimer and compositions containing the same

Country Status (31)

Country Link
US (1) US6132715A (enExample)
EP (1) EP0651654B1 (enExample)
JP (1) JPH07508744A (enExample)
KR (1) KR100289841B1 (enExample)
CN (1) CN1057937C (enExample)
AT (1) ATE252392T1 (enExample)
AU (1) AU677786B2 (enExample)
BG (1) BG63331B1 (enExample)
BR (1) BR9306722A (enExample)
CA (1) CA2140140A1 (enExample)
CZ (1) CZ286725B6 (enExample)
DE (2) DE651654T1 (enExample)
DK (1) DK0651654T3 (enExample)
ES (1) ES2074037T3 (enExample)
FI (1) FI950144A0 (enExample)
GE (1) GEP20012466B (enExample)
GR (1) GR950300039T1 (enExample)
HU (1) HU218151B (enExample)
MX (1) MX9304197A (enExample)
NZ (2) NZ254135A (enExample)
OA (1) OA10125A (enExample)
PL (1) PL173978B1 (enExample)
PT (1) PT651654E (enExample)
RO (1) RO112580B1 (enExample)
RU (1) RU2145875C1 (enExample)
SG (1) SG52727A1 (enExample)
SK (1) SK282377B6 (enExample)
TW (1) TW259710B (enExample)
UA (1) UA49789C2 (enExample)
WO (1) WO1994001127A1 (enExample)
ZA (1) ZA935046B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105106626A (zh) * 2015-09-30 2015-12-02 成都倍加特生物科技有限公司 一种治疗月经期感染的汤剂药物及其制备方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183742B1 (en) 1992-07-13 2001-02-06 Nika Health Products, Limited Applications of lysozyme dimer
DZ1964A1 (fr) * 1995-01-13 2002-10-15 Nika Health Products Ltd Nouvelle applications d'un dimère de lysozyme.
JPH10507200A (ja) * 1995-05-30 1998-07-14 リジェール ファーマシューティカルズ，インコーポレイティド 下りものの凝集及び回収のためのレクチンの使用方法
US6123937A (en) * 1997-03-14 2000-09-26 Nika Health Products, Limited Applications of lysozyme dimer
ITMI981148A1 (it) * 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
EP1174147A1 (en) * 2000-06-27 2002-01-23 Nika Health Products Limited Reversal of antibiotic resistance with lysozyme dimer
US20050244402A1 (en) * 2004-04-30 2005-11-03 Villanueva Julie M Absorption of pain-causing agents
RU2320367C1 (ru) * 2006-08-22 2008-03-27 Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию (ГОУ ДПО РМАПО Росздрава) Способ сопроводительного лечения острого лимфобластного лейкоза
RU2351351C1 (ru) * 2007-08-08 2009-04-10 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, повышающее неспецифическую сопротивляемость организма к бактериальным эндотоксинам
RU2472467C2 (ru) * 2011-04-13 2013-01-20 Государственное научное учреждение Краснодарский научно-исследовательский ветеринарный институт (ГНУ КНИВИ) Способ профилактики и лечения гастроэнтеритов, обусловленных бактериозами, у телят

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4020M (enExample) * 1965-01-29 1966-03-21
FR2215201A1 (en) * 1973-01-24 1974-08-23 Theranol Lab Broad-spectrum antibiotic compsns. - contg. antibiotic resistant lactic bacilli and enzyme diffusing-agent
JPS5533408A (en) * 1978-08-30 1980-03-08 Eisai Co Ltd Immunity-increasing agent
JPS5533409A (en) * 1978-08-30 1980-03-08 Eisai Co Ltd Carcinostatic agent
JPS5543040A (en) * 1978-09-25 1980-03-26 Eisai Co Ltd Immunity raising agent
US4221794A (en) * 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4457919A (en) * 1980-03-14 1984-07-03 Newport Pharmaceutical International, Inc. Method of imparting immunomodulating, antiviral or antitumor activity
US4510144A (en) * 1981-08-26 1985-04-09 Newport Pharmaceuticals International Methods of imparting immunomodulating activity with dihydrothiazolo purine derivatives
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
DE3782958D1 (de) * 1986-02-19 1993-01-21 Imreg Inc Verfahren und mittel zum pruefen eines immunsystems.
RU2092183C1 (ru) * 1988-05-26 1997-10-10 Ника Хелт Продактс Лимитед (Лихтенштейн) Антивирусный или антибактериальный состав и способ его употребления
DE3817955A1 (de) * 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
AU3765689A (en) * 1988-05-31 1990-01-05 Napp Systems (U.S.A.) Inc. Apparatus and process for processing printing plates
JPH05503919A (ja) * 1989-06-13 1993-06-24 スミスクライン・ビーチャム・コーポレイション 単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制
HU214509B (hu) * 1990-01-08 1998-03-30 Nika Health Products Ltd. Eljárás tisztított lizozim dimerek előállítására
US5314816A (en) * 1990-01-08 1994-05-24 Nika Health Products Ltd. Method of preparing lysozyme dimers
WO1992002220A1 (en) * 1990-08-03 1992-02-20 Smithkline Beecham Corporation Tnf inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105106626A (zh) * 2015-09-30 2015-12-02 成都倍加特生物科技有限公司 一种治疗月经期感染的汤剂药物及其制备方法

Also Published As

Publication number Publication date
ATE252392T1 (de) 2003-11-15
RO112580B1 (ro) 1997-11-28
BG63331B1 (bg) 2001-10-31
FI950144L (fi) 1995-01-12
CN1087278A (zh) 1994-06-01
US6132715A (en) 2000-10-17
SG52727A1 (en) 1998-09-28
ES2074037T1 (es) 1995-09-01
HU218151B (hu) 2000-06-28
PT651654E (pt) 2004-03-31
GR950300039T1 (en) 1995-07-31
WO1994001127A1 (en) 1994-01-20
HU9500098D0 (en) 1995-03-28
DE69333258D1 (de) 2003-11-27
ZA935046B (en) 1994-02-07
HUT70973A (en) 1995-11-28
PL295273A1 (en) 1994-01-24
FI950144A7 (fi) 1995-01-12
CN1057937C (zh) 2000-11-01
DE69333258T2 (de) 2004-08-26
NZ299377A (en) 2001-02-23
OA10125A (en) 1996-12-18
DE651654T1 (de) 1996-01-04
AU677786B2 (en) 1997-05-08
FI950144A0 (fi) 1995-01-12
TW259710B (enExample) 1995-10-11
KR100289841B1 (ko) 2001-05-15
NZ254135A (en) 1996-11-26
MX9304197A (es) 1994-02-28
EP0651654B1 (en) 2003-10-22
SK4095A3 (en) 1995-09-13
ES2074037T3 (es) 2004-07-01
DK0651654T3 (da) 2004-02-23
KR950702432A (ko) 1995-07-29
SK282377B6 (sk) 2002-01-07
GEP20012466B (en) 2001-06-25
CZ8595A3 (en) 1995-09-13
PL173978B1 (pl) 1998-05-29
JPH07508744A (ja) 1995-09-28
RU2145875C1 (ru) 2000-02-27
BG99287A (bg) 1995-08-28
BR9306722A (pt) 1998-12-08
AU4568693A (en) 1994-01-31
UA49789C2 (uk) 2002-10-15
EP0651654A1 (en) 1995-05-10
CZ286725B6 (en) 2000-06-14

Similar Documents

Publication Publication Date Title
Miyamoto et al. Antitumor activity of oenothein B, a unique macrocyclic ellagitannin
US5466449A (en) Antibacterial composition and method of use
Kohchi et al. Applications of lipopolysaccharide derived from Pantoea agglomerans (IP-PA1) for health care based on macrophage network theory
CA2140140A1 (en) Lysozyme dimer and compositions containing the same
KR101279196B1 (ko) 살균성, 정균성 및 항염증을 위한 방법 및 조성물
EP0405315B1 (en) Use of a phagocyte-activating agent : LPS or IL-2 for the manufacture of a medicament for treating staphylococcus aureus infection in cows
HUT67071A (en) Method of treating or preventing mastitis of animals with involuting hammary glands by administering recombinant citokines
Schade et al. Endotoxin-tolerant mice produce an inhibitor of tumor necrosis factor synthesis
Pierangeli et al. Treatment of murine macrophages with murine interferon-gamma and tumour necrosis factor-alpha enhances uptake and intracellular killing of Pseudomonas aeruginosa
EP0548558A2 (en) Compositions containing surfactants as potentiating agents for the treatment of mammalian diseases
Mayer et al. Porcine alveolar macrophages, isolation, morphological and functional characteristics
Brown et al. Muramyl dipeptide enhances survival from experimental peritonitis
PL176407B1 (pl) Kompozycja farmaceutyczna zawierająca dimer lizozymu
Chirigos et al. Cellular regulation by immunomodifiers MVE-2 and poly-ICLC and their therapeutic application
Aswad et al. Formulation and Evaluation of Snakehead Fish Mucus Emulgel for Enhanced Wound Healing and Antibacterial Activity
Rosenberg Use of cefoperazone in the empiric treatment of serious skin infections
US3772438A (en) Antibiotic compositions containing coumermycin
Assiri et al. Assessment of Cytokine Release in Septic Shock Induced by Some Antibiotics

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued